NCT05340309 - Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 7, 2022

Primary Completion Date

July 29, 2025

Study Completion Date

July 29, 2025

Conditions

Lung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8Stage IIA Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8

Interventions

BIOLOGICAL

Atezolizumab and Recombinant Human Hyaluronidase

Given SC

OTHER

Survey Administration

Ancillary studies

Trial Locations (1)

90033

USC / Norris Comprehensive Cancer Center, Los Angeles